Keel Point’s Moderna MRNA Stock Holding History

Keel Point’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-565	Closed	-$217K	–	283
2021 Q3	$217K	Buy	+565	New	+$208K	0.03%	243

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Keel Point's MRNA Position: Q4 2021 in Review

Keel Point sold out of Moderna (MRNA) in Q4 2021, closing a stake of 565 shares — an estimated $217K sold.

Keel Point first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $217K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Keel Point reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Keel Point sold 565 Moderna shares in Q4 2021, an estimated $217K.
Keel Point first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Keel Point's Moderna position peaked at $217K in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Keel Point's 13F filing for Q4 2021, filed 31 Jan 2022.